Here we present Nlrx1 as a prospective host-targeted therapeutic for fungal infections that is involved in regulating the intensity and type of immune response to A. fumigatus in several pre-clinical models of IPA. This evidence concerns the gene NLRX1 and Ito hypomelanosis.